Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study
Posted
Frank Vinluan (via MedCity News)
The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.
The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News.
